Page 1
1
Changes Impacting Bioequivalence Inspections: What’s New?
Sam H. Haidar, Ph.D., R.Ph.
Division of Generic Drug Bioequivalence Evaluation Office of Study Integrity and Surveillance Center for Drug Evaluation and Research
U.S. Food and Drug Administration
2nd MENA Regulatory Conference on BE, Biowaiver, Bioanalysis, Dissolution and Biomarkers Amman, Jordan, September 15, 2015
Page 2
2
Outline
● Organizational changes/New regulatory developments: Impact on BE inspections
● FDA’s BE inspectional program, focus on
bioanalytical inspections
● Selected topics for discussion
Page 3
3
Organization Prior to January 11, 2015
Page 4
4
Office of Compliance
Office of Scientific Investigations
Office of Drug Security, Integrity & Recalls
Office of Manufacturing & Product Quality
Office of Unapproved Drugs and Labeling Compliance
Office of the Center Director Janet Woodcock, MD, Director
Center for Drug Evaluation and Research
Page 5
5
Office of Scientific Investigations Director
Immediate Office Policy & Communication Risk Science, Intelligence & Prioritization Program Management and Organizational Strategy
Division of
Bioequivalence & GLP
Division of GCP Compliance
Division of Safety Compliance
Page 6
6
Organization Post January 11, 2015
Page 7
7
Office of Translational Science
Office of Study Integrity and Surveillance Office of Clinical Pharmacology
Office of Biostatistics Office of Computational Science
Office of the Center Director Janet Woodcock, MD, Director
Center for Drug Evaluation and Research
Page 8
8
Division of Generic Drug BE Evaluation
Division of New Drug BE Evaluation
Office of Study Integrity and Surveillance (OSIS)
BE BE BE BE BE GLP
Page 9
Regulatory Developments
• Generic Drug User Fee Amendments of 2012 (GDUFA)
• Biologics Price Competition and Innovation Act of 2009 – Section 351(k) “Licensure of Biological
Products as Biosimilar or Interchangeable.”
9
Page 10
Evolution of Procedures After Re-organization
• Inspectional data: Site specific vs. study specific
• Surveillance approach-parts of multiple studies
• Analytical inspections with and without ORA participation
• More large molecule PK assays, immunogenicity testing
10
Page 11
11
Points to Remember…
● Primary objective of any study should be to pursue good science, and good documentation
● Guidances do not and cannot address every aspect of every study
● Guidances provide best recommendations based on what we currently know (i.e., not regulations)
● By themselves, Guidances are not binding on FDA or industry
Page 12
12
FDA’s BE Inspection Program
Type of studies:
• In vivo studies – Bioavailability (BA), BE, pharmacokinetic (PK),
pharmacodynamic (PD), clinical endpoint BE studies
• In vitro data – Biowaiver permeability studies – Nasal aerosols and sprays for local action – Binding studies: Phosphate, calcium, bile acids
Page 13
13
FDA’s BE Inspection Program
Biologics, Biosimilar Studies: – Pharmacokinetic data (ELISA, ECL*, GyroLab)
– Immunogenicity data (anti-drug antibodies [ADA],
neutralizing antibodies [NAb]) • ELISA, ECL, RIP** • Cell-based (neutralizing)
*Electrochemiluminescense
**Radioimmunoprecipitation
Page 14
14
BE Inspections
Inspection type: Routine, surveillance Studies pivotal to approval decisions (NDAs,
ANDAs, BLAs); other studies submitted to FDA “For Cause” Concerns with study conduct or reported results Complaint follow-up
Page 15
15
Two components:
1. Clinical: Office of Regulatory Affairs (ORA)
2. Bioanalytical: ORA + Office of Study Integrity and Surveillance (OSIS); option: No ORA participation
In Vivo BE Inspections
Page 16
16
Clinical Inspections
Key Elements Subject safety Informed consent Reserve Samples-test and reference,
per regulations Adherence to study protocol Adequate documentation
Page 17
17
Bioanalytical Inspections
Key Elements
Facility Walk-Through
Handling and storage of subject samples
Assay validation
Page 18
18
Bioanalytical Inspections
Primary Objectives:
Evaluate adherence to regulations, guidances, and scientific principles
Ensure data quality and integrity
Adequate documentation-Paper and Electronic Allow reconstruction of the study
Page 19
19
Bioanalytical Inspections Examples of Areas Covered
• Storage (freezers, appropriate temp), limited access, alarms
• Samples: chain of custody, storage, extractions, LC-MS/MS system, equilibration samples, audit trails, manual integration, carry-over effect, interference, reproducibility (ISR*)
• Light Sensitivity • Archival area
*Incurred sample reproducibility
Page 20
20
Data Audit
• Assay Validation
• Comparison of data submitted by sponsor in application to source records on site
• Sample reanalysis: Justified? Well documented?
Page 21
21
Data Quality
• QC samples-range covers observed subject concentrations?
• Standard curve-appropriate range
• Run acceptance
• Carryover effect/interference
• ISR
Page 22
22
Data Integrity
• Audit trails-manual integration – Electronic data management
• Contemporaneous documentation
• Correspondence File
Page 23
23
Inspectional Outcomes
• No observations/NAI
• Form FDA 483, Observations/VAI*
• Form FDA 483, Observations/OAI*
NAI: No Action Indicated; VAI: Voluntary Action Indicated; OAI: Official Action Indicated *Site has 15 business days to respond
Page 24
24
Inspectional Outcomes
• Recommendations are made to the review divisions (OGD, OND) to accept or reject data (partial or full)
• For OAI Classification, the Office of Compliance issues a regulatory letter to the inspected entity
Page 25
25
Common/Serious Observations
• Reserve samples: In vivo, In vitro studies – Rejection of data
• Assay Validation-Accuracy, precision, stability, sensitivity, selectivity
• Quality Controls-Inappropriate acceptance of analyzed run
• Documentation
Page 26
26
References • FDA Regulations – 21 CFR 320
– Bioavailability and Bioequivalence Requirements
• FDA Guidance document – “Bioanalytical Method Validation”
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf
• Compliance Program Guidance Manual
– In Vivo Bioequivalence Program 7348.001 http://www.fda.gov/downloads/ICECI/EnforcementActions/BioresearchMonitoring/UCM133760.pdf
Page 27
Special Topics for Discussion
• Processed vs. Instrumental Batches
• Extract Stability
• Incurred Sample Stability (ISS)
• Long term stability for combination or co-administered drugs
27
Page 28
Special Topics for Discussion
• Internal Standard Response
• Handling of Outliers
28